Home > Boards > US OTC > Biotechs > U.S. Stem Cell Inc. (USRM)

Interesting timing on this new flexibility from the

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Xpecht Member Profile
 
Followed By 2
Posts 200
Boards Moderated 0
Alias Born 03/29/17
160x600 placeholder
Xpecht   Monday, 02/25/19 11:35:24 PM
Re: None
Post # of 106460 
Interesting timing on this new flexibility from the FDA. Bring back MyoCell RMAT and while we’re at it the Hungry Hippo as well! Lol

The path wasn’t clear for Tomas and USRM to continue to spend money on the RMAT application. Is the path more clear now?

USRM has spent more than $100 million over two decades on both preclinical (animal) and clinical (human) trials using its MyoCell™ product. The trials published to date show culture-expanded autologous stem cells directly injected into the heart can provide benefit to congestive heart failure patients

(review full publication here: https://www.ncbi.nlm.nih.gov/pubmed/21982657)


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences